Dr Kevin Buckman Named Chairman and CEO of Vantage Health
July 29 2014 - 3:51PM
Business Wire
-Preliminary human clinical trials are
anticipated to begin next month-
Vantage Health (the “Company”) (OTCQB:VNTH) today announced the
appointment of Kevin Buckman MD FAAIM, DAAUCM, MACOEM, MRO as
Chairman and CEO of the Company.
The Company also announced that Mr. Jeremy Barbera, its current
Chairman and CEO, is resigning as an officer and director of
the Company and will focus on the scientific aspects of the
Company’s technology in a non-executive capacity. This action is
due, in part, to certain matters involving a company with
which Mr. Barbera was associated several years ago. These
matters are unrelated to the Company or any aspect of its
technology or business.
It is anticipated that preliminary human trials for the Vantage
Health Sensor will begin next month at Scripps Translational
Science Institute, paid for by a BioPharma partner of the Company.
Mr. Barbera will continue to be Chairman and CEO of Nanobeak, which
is the private company majority shareholder of Vantage Health.
Dr. Buckman completed his medical training in internal medicine
in 1981. He began his research in 1977 in the fields of
immunology, cancer, diabetes, and chronic diseases. His
discoveries of the roles of inflammation and abnormal cellular
environments in cancers and immune diseases have made him a leader
in the field. His research has led to his interest in
technologies in early diagnosis and treatments, especially in the
field of breast cancer. He recently published a book on the
subject, Find and Stop Breast Cancer, as well as a book
on solutions for diabetes and metabolic syndrome, titled Find
and Stop Diabetes. He has worked internationally to advance a
number of medical technologies with a focus on early detection of
disease, with a primary focus on breast cancer and diabetes.
Dr. Buckman has served as Medical Director in various hospitals
and institutions for over 25 years and has over 30 years of
hospital and clinical experience. He became Board Certified in
Emergency Medicine and a Fellow of the American Board of Emergency
Medicine in 1990. In 2006 he became Board Certified in Urgent Care
Medicine and a Diplomat. He also became a Fellow of the American
Association of Integrated Medicine, and a Certified Medical Review
Officer.
Dr. Buckman was the first US Physician to be accepted into the
European Group for Breast Cancer Screening. He received some
post-graduate training at Stanford University School of Business.
He is also the Co-Founder of cancer.im, a 501(c)(3) non-profit
organization for cancer research. Dr. Buckman also serves as CEO of
Viratech Corp., which provides open source research using
social networks.
About Vantage Health
Vantage Health - a mobile health technology company - is
developing personalized and point-of-care screening using Apps
based upon chemical sensing residing within a small device attached
to a smartphone. With its foundations in advanced nanotechnology,
the Company’s first product, the Vantage Health Sensor, is the
convergence of nano-electronics, bio-informatics, and wireless
technology to create the next generation mobile health application.
The first mobile App is expected to be for lung cancer screening
with additional mobile healthcare Apps in the planning stages. The
company has offices in Redwood City, CA and New York. For more
information, please visit http://www.vantagehealthinc.com
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include, among other
things statements with respect to our objectives and strategies to
achieve those objectives, as well as statements with respect to our
beliefs, plans, expectations, anticipations, estimates or
intentions. Such forward-looking statements may also include
statements, among other things, concerning the efficacy, safety and
intended utilization of the Company’s product candidates, the
conduct and results of future clinical trials, plans regarding
regulatory filings, future research and clinical trials and plans
regarding partnering activities. Factors that may cause actual
results to differ materially include, among others, the risk that
product candidates that appeared promising in early research and
clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later clinical trials, trials may have difficulty
enrolling, the Company may not obtain approval to market its
product candidates, or outside financing may not be available to
meet capital requirements. These forward-looking statements are
based on our current expectations. We caution that all
forward-looking information is inherently uncertain and actual
results may differ materially from the assumptions, estimates or
expectations reflected or contained in the forward-looking
information, and that actual future performance will be affected by
a number of factors, including economic conditions, technological
change, regulatory change and competitive factors, many of which
are beyond our control. Therefore, future events and results may
vary significantly from what we currently foresee.
For a further list and description of the risks and
uncertainties the Company faces, please refer to the Company’s most
recent Annual Report on Form 10-K and other periodic and other
filings the Company files with the Securities and Exchange
Commission and are available at www.sec.gov. Such forward-looking
statements are current only as of the date they are made, and the
Company assumes no obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investors:CSIR Group, LLC.Christine Petraglia, 212-386-7082
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jul 2023 to Jul 2024